JANX
Janux Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.75 / 10
Netural
Analyst coverage is lukewarm: two analysts rate the stock Neutral or Buy with a 1.92 weighted score. Fund-flow metrics lean positive (score 7.57/10) despite negative trends in block and large-inflow ratios. The blend of moderate analyst support and tepid institutional participation underscores a wait-and-see sentiment.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-20
InstitutionClear Street
Times predicted2
Historical Win Rate50.0%
Is money flowing into or out of JANX?
- JANX holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.75/10 (Netural).
